上海，2022年12月21日—药明康德今日宣布入选2022道琼斯可持续发展世界指数（DJSI World）。此次入选充分证明了药明康德致力于将环境、社会及管治（ESG）融入公司战略和运营的坚定信念和出色成绩。
道琼斯可持续发展世界指数由标普全球的企业可持续发展评估（CSA）选出的可持续发展领导者组成。该评估以经济、环境和社会效益为基准对全球大型公司进行综合衡量，代表了标准普尔全球BMI指数中最大的2500家公司中排名前10%的公司。此次评估中，药明康德的评分超出行业平均分近3倍，并在参评的全球72家生命科学工具和服务企业中排名前3%。
“这次入选道琼斯可持续发展世界指数，是药明康德积极践行ESG理念、将ESG融入到战略和运营方方面面的证明，”药明康德副董事长兼ESG委员会主席胡正国先生表示。“我们将继续坚持可持续发展，履行企业社会责任，助力合作伙伴加速新药和突破性疗法的问世，造福全球病患。”
作为全球领先的新药研发赋能平台，药明康德不断夯实管理体系，在全球范围内开展ESG工作，持续提升各运营地的管理水平。2022年，药明康德被知名评级机构Sustainalytics评为“低风险”企业并位列全球医药行业前2%。同时，公司在摩根士丹利资本国际公司（MSCI）的ESG评级中再次被评为“AA级”，并在CDP气候问卷评级中首次获得领导力级别的“A-级”。与此同时，公司也连续第二年被纳入道琼斯可持续发展新兴市场指数。
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2022年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5900多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index
Shanghai, December 21, 2022 – WuXi AppTec, a leading global provider of R D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability? World Index (DJSI). This demonstrates the company’s strong performance and commitment to Environmental, Social and Governance (ESG) initiatives.
The Dow Jones Sustainability? World Index comprises global sustainability leaders as identified by S P Global through the Corporate Sustainability Assessment (CSA). It represents the top 10% of the largest 2,500 companies in the S P Global BMI based on long-term economic, environmental and social criteria. In this evaluation, WuXi AppTec scored three times higher than the industry average and placed in the top 3% among 72 global leading companies reviewed in the Life Sciences Tools Services sector.
“Inclusion in the Dow Jones Sustainability World Index is a testament to WuXi AppTec’s efforts to integrate ESG into every aspect of our business strategy and operations,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee.“We will continue to prioritize our ESG commitments while enabling our customers’ discovery, development and manufacturing of innovative medicines and groundbreaking therapies for patients around the world.”
WuXi AppTec continues to enhance its ESG management system and prioritize ESG initiatives across its operations. In 2022, WuXi AppTec was awarded a “Low Risk” rating and ranked in the top 2% of the global pharmaceutical industry by Sustainalytics. WuXi AppTec was also recently granted an “AA” rating again from Morgan Stanley Capital International (MSCI) and received a leadership level of “A-” in the CDP Climate Change rating for the first time. In addition, WuXi AppTec has been named to the Dow Jones Sustainability Emerging Markets Index for a second consecutive year.
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 5,900 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
分享，点赞，在看，聚焦全球生物医药健康创新